TCM Biotech International Corp. (TPE:4169)
149.00
+0.50 (0.34%)
Aug 19, 2026, 1:30 PM CST
TCM Biotech International Revenue
TCM Biotech International had revenue of 181.09M TWD in the quarter ending June 30, 2026, a decrease of -0.80%. This brings the company's revenue in the last twelve months to 701.63M, up 4.03% year-over-year. In the year 2025, TCM Biotech International had annual revenue of 685.49M with 2.84% growth.
Revenue (ttm)
701.63M
Revenue Growth
+4.03%
P/S Ratio
12.50
Revenue / Employee
n/a
Employees
n/a
Market Cap
8.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 685.49M | 18.96M | 2.84% |
| Dec 31, 2024 | 666.53M | -303.09M | -31.26% |
| Dec 31, 2023 | 969.62M | 167.20M | 20.84% |
| Dec 31, 2022 | 802.42M | 100.38M | 14.30% |
| Dec 31, 2021 | 702.05M | -35.03M | -4.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Adimmune | 1.41B |
| Savior Lifetec | 1.12B |
| PharmaEngine | 1.03B |
| Tanvex BioPharma | 483.94M |
| TaiGen Biopharmaceuticals Holdings | 258.93M |
| Polaris Group | 69.27M |
| Gongwin Biopharm Holdings | 38.28M |